Invention Grant
US08999390B2 Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
有权
包含奥曲肽和三种直链聚丙交酯 - 共 - 乙交酯聚合物的缓释制剂
- Patent Title: Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
- Patent Title (中): 包含奥曲肽和三种直链聚丙交酯 - 共 - 乙交酯聚合物的缓释制剂
-
Application No.: US13472219Application Date: 2012-05-15
-
Publication No.: US08999390B2Publication Date: 2015-04-07
- Inventor: Holger Petersen , Markus Ahlheim
- Applicant: Holger Petersen , Markus Ahlheim
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Gregory Houghton; George R. Dohmann
- Priority: EP08150826 20080130
- Main IPC: A61K9/14
- IPC: A61K9/14 ; A61K38/31 ; A61K9/16 ; A61K9/00 ; A61K9/06 ; A61K9/10
Abstract:
The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).
Public/Granted literature
- US20120226224A1 SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND THREE LINEAR POLYLACTIDE-CO-GLYCOLIDE POLYMERS Public/Granted day:2012-09-06
Information query
